title: [Achievement of goal resting heart rate in patients with stable angina and hypertension at the background of therapy with -adrenoblockers in real clinical practice].
abstract: β-Adrenoblockers improve quality of life and in a number of cases life prognosis in patients with stable angina (SA). Dose of -adrenoblockers is considered optimal if at the background of treatment resting heart rate (rHR) is persistently decreased down to 55-60 bpm. But according to data of international registries rate of achievement of target rHR (trHR) in real clinical practice does not exceed 22%. Aim of this study was to determine what portion of patients with SA and arterial hypertension (AH) achieves trHR at the background of therapy with -adrenoblockers in routine practice in this country. Twenty centers in 6 towns in Russian Federation recruited 399 patients (mean age 64+/-10 years) with class I-III angina and concomitant primary AH. These patients for at least 2 months received any -adrenoblocker and did not change its dose during 4 weeks before inclusion into the program. Portion of patients with trHR was 15.5%. There were no significant differences between average daily doses of most frequently used -adrenoblockers (metoprolol, bisoprolol, carvediolol) in groups of patients who achieved and did not achieve trHR. Quality of life of patients who achieved was comparable with that of those who did not achieve trHR. Attainment of trHR was associated with significant decrease of short acting requirement nitrates. There was a significant direct correlation between attainment of trHR and target arterial pressure.
authors.affiliation: Russian University of Peoples Friendship, ul. Mikluho-Maklaya, 6,117198 Moscow, Russia.
authors.forename: Zh D
authors.initials: ZhD
authors.lastname: Kobalava
authors.forename: G K
authors.initials: GK
authors.lastname: Kiiakbaev
authors.forename: Iu V
authors.initials: IuV
authors.lastname: Khomitskaia
authors.forename: A A
authors.initials: AA
authors.lastname: Shavarov
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage*; D000368:Aged; D060050:Angina, Stable / Q000150:complications / Q000188:drug therapy* / Q000453:epidemiology / Q000503:physiopathology / Q000523:psychology; D001794:Blood Pressure / Q000187:drug effects; D003710:Demography; D004305:Dose-Response Relationship, Drug; D016903:Drug Monitoring; D005260:Female; D006339:Heart Rate / Q000187:drug effects*; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000188:drug therapy* / Q000453:epidemiology / Q000503:physiopathology / Q000523:psychology; D008297:Male; D008875:Middle Aged; D011788:Quality of Life; D012426:Russia / Q000453:epidemiology; D012720:Severity of Illness Index; D011795:Surveys and Questionnaires; D016896:Treatment Outcome
chemical_list: D000319:Adrenergic beta-Antagonists